$CLDX SEC Filings

Filed On	Filing
07 Oct 2026	SCHEDULE 13G/A
22 Sep 2026	8-K: Other Events Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
15 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
29 Jun 2026	Form 4: Lawver Teri L, SVP & Chief Commercial Officer Granted 90,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Jimenez Freddy A., SVP & GENERAL COUNSEL Granted 93,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Young Diane C., SVP, CHIEF MEDICAL OFFICER Granted 57,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Heath-Chiozzi Margo, SVP OF REGULATORY AFFAIRS Granted 95,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Martin Samuel Bates, SVP AND CFO Granted 93,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Cavanaugh Sarah, SVP OF CORP AFFAIRS & ADMIN. Granted 95,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Crowley Elizabeth, SR. VP & CPDO Granted 100,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Pepin Ronald, SR. VP & CBO Granted 20,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Keler Tibor, EXECUTIVE VP & CSO Granted 115,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Marucci Anthony S, Director Granted 375,000 Incentive Stock Option (right to buy)
29 Jun 2026	Form 4: Torres Denice, Director Granted 26,000 Non-Qualified Stock Option (right to buy)
29 Jun 2026	Form 4: Jain Rita, Director Granted 26,000 Non-Qualified Stock Option (right to buy)
29 Jun 2026	Form 4: Neil Garry Arthur, Director Granted 26,000 Non-Qualified Stock Option (right to buy)

Comments